Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155000 | 0.85 | SIGMAR1 (0.65) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1639608 | 0.85 | SIGMAR1 (0.65) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1041303 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL242970 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1639911 | 0.79 | SIGMAR1 (0.71) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1415730 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL576868 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL8188324 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2489199 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL4448723 | 0.77 | SIGMAR1 (0.68) | SIGMAR1MC4RDRD4LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-2567951-B1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3334733-A1 | 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Pfizer Inc (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3301086-A1 | PRODUCTION OF A COMPOSITION CONTAINING A COMPLEX BETWEEN A MEMBRANE COMPOSED OF A LIPID MONOLAYER AND A NUCLEIC ACID, AND, A LIPID MEMBRANE FOR ENCAPSULATING THE COMPLEX THEREIN | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9920028-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20170349532-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| WO-2017025868-A1 | 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PFIZER INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20160304487-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-10-20 | — | — | US | disclosed |
| EP-2774912-A1 | CATIONIC LIPID | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-09-10 | — | — | EP | disclosed |
| US-20130108685-A1 | CATIONIC LIPID | KYOWA KIRIN CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| EP-1776395-B1 | POLYMERIZATION CATALYSTS, MAIN GROUP COORDINATION COMPOUNDS, PROCESS FOR PREPARING POLYOLEFINS AND POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7750097-B2 | Polymerization catalysts, main group coordination compounds, process for preparing polyolefins and polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7544749-B2 | Polymerization catalysts, organic transition metal compounds, process for preparing polyolefins and polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-20080021182-A1 | Polymerization Catalysts, Main Group Coordination Compounds, Process For Preparing Polyolefins And Polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2008-01-24 | — | — | US | disclosed |
| EP-1590377-B1 | POLYMERIZATION CATALYSTS, ORGANIC TRANSITION METAL COMPOUNDS, PROCESS FOR PREPARING POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2007-06-13 | — | — | EP | disclosed |
| EP-1776395-A1 | POLYMERIZATION CATALYSTS, MAIN GROUP COORDINATION COMPOUNDS, PROCESS FOR PREPARING POLYOLEFINS AND POLYOLEFINS | Basell Polyolefine GmbH (DE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060100092-A1 | Polymerization catalysts, organic transition metal compounds, process for preparing polyolefins and polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006002923-A1 | POLYMERIZATION CATALYSTS, MAIN GROUP COORDINATION COMPOUNDS, PROCESS FOR PREPARING POLYOLEFINS AND POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1590377-A1 | POLYMERIZATION CATALYSTS, ORGANIC TRANSITION METAL COMPOUNDS, PROCESS FOR PREPARING POLYOLEFINS AND POLYOLEFINS | Basell Polyolefine GmbH (DE) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069881-A1 | POLYMERIZATION CATALYSTS, ORGANIC TRANSITION METAL COMPOUNDS, PROCESS FOR PREPARING POLYOLEFINS AND POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304487-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | SIGMAR1 143/4885MC4R 3589/4885DRD4 1592/4885 |
| US-20170349532-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | SIGMAR1 143/4885MC4R 3589/4885DRD4 1592/4885 |
| US-20080021182-A1 | Polymerization Catalysts, Main Group Coordination Compounds, Process For Preparing Polyolefins And Polyolefins | PCNA, PARG, TST | SIGMAR1 3262/4885MC4R 3734/4885DRD4 1196/4885 |
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | TDO2, IDO1, IDO2 | SIGMAR1 1168/4885MC4R 845/4885DRD4 427/4885 |
| US-20130108685-A1 | CATIONIC LIPID | LPAR3, ACOX3, H1-3 | SIGMAR1 143/4885MC4R 3589/4885DRD4 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.